Atavistik Bio
Cambridge · Biotechnology, Health Care, Science And Engineering
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the
Key facts
- Headquarters
- Cambridge
- Employees
- 38
- Industries
- Biotechnology, Health Care, Science And Engineering
- Status
- Private
- Website
- atavistikbio.com
- Company page
Recent activity at Atavistik Bio
- : Roche enters a research partnership with Atavistik Bio with a USD 70 million upfront payment. (date Fundz recorded it)
- : Atavistik Bio raises $120M in Series B financing, led by Nextech Invest and The Column Group, to advance treatments for Hereditary Hemorrhagic Telangiectasia and myeloproliferative neoplasms.
- : Atavistik Bio Appoints Susan Pandya as Chief Medical Officer
- : Atavistik Bio and Pfizer Collaborate to Discover Novel Allosteric Therapeutics (date Fundz recorded it)
- : Atavistik Bio Unveils Promising Preclinical Data for ATV-1601, a Small Molecule Inhibitor Targeting AKT1 E17K Mutations
- : Atavistik Bio Appoints Paul Bruno, Ph.D. as Chief Business Officer
- : Atavistik Bio Raises Additional $40 Million To Advance Precision Allosteric Small Molecule Therapeutics
- : Atavistik Bio Appoints Bryan Stuart as Chief Executive
- : Atavistik Bio Announces $60 Million Series A Financing To Advance Genetically-Validated Targets In Metabolic Diseases And Cancer
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Atavistik Bio funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Series B | $120.0M |
| Dec 2023 | Funding Round | $40.0M |
| Aug 2021 | Series A | $60.0M |
Leadership
- Susan Pandya, Chief Medical Officer
- Paul Bruno, Chief Business Officer
- Marion Dorsch, Chief Scientific Officer
- Bryan Stuart, Chief Executive Officer
Verified email and direct lines for Atavistik Bio’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Atavistik Bio files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Atavistik Bio in the news
- Atavistik Bio Holds $120 Million Series B Financing to Advance Small Molecule Therapies for HHT and MPNs - Pharmaceutical Executive (Dec 19, 2025)
- Atavistik Bio Announces Strategic Research Collaboration - GlobeNewswire (Sep 24, 2026)
- Atavistik Bio Appoints Habib Dable to its Board of Directors - GlobeNewswire (Jul 29, 2026)
- Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer - Business Wire (Aug 24, 2021)
- Atavistik Bio Closes $40 Million Series B Extension for - GlobeNewswire (Mar 05, 2026)
- Atavistik Bio Raises $120 Million Series B Financing to - GlobeNewswire (Dec 18, 2025)
- Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference - GlobeNewswire (Oct 07, 2026)
- Atavistik Bio Announces Research Collaboration with Pfizer - GlobeNewswire (Jan 02, 2025)
Companies similar to Atavistik Bio
- Nucleai · Biotechnology, Health Care, Science And Engineering, Software
- Stilla Technologies · Biotechnology, Health Care, Science And Engineering, Software
- RedHill Biopharma Ltd · Biotechnology, Health Care, Science And Engineering, Software
- Sequentify · Biotechnology, Health Care, Science And Engineering, Software
- Zephyr AI, Inc. · Biotechnology, Health Care, Science And Engineering, Software
About Atavistik Bio: questions and answers
What does Atavistik Bio do?
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the
Where is Atavistik Bio headquartered?
Atavistik Bio is headquartered in Cambridge.
How many employees does Atavistik Bio have?
Atavistik Bio has about 38 employees.
Has Atavistik Bio raised funding?
Yes. Fundz has recorded 3 funding events for Atavistik Bio. The most recent, Series B of $120.0M, was in Dec 2025.
Who leads Atavistik Bio?
Bryan Stuart is a Chief Executive Officer at Atavistik Bio.
What is the latest news on Atavistik Bio?
On Sep 25, 2026, Roche enters a research partnership with Atavistik Bio with a USD 70 million upfront payment.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy